Industries›24 companies · latest full-year results
An industry that conducts research and development, manufacturing, and sales of pharmaceuticals. Contributes to maintaining and improving people's health.
The 24 pharmaceutical companies we cover had combined revenue of ¥19.8T (+5.0% year over year) and operating profit of ¥2.8T, an industry-wide operating margin of 13.9%.
Takeda leads on revenue (¥4.5T, a 22.8% share), and the top three hold 48% of industry sales. 10 grew both revenue and operating profit; 0 saw both fall.
Chugai has the highest operating margin (47.6%); average pay across the industry is ¥9.57M, highest at Nxera (¥12.6M).
Industry total
Pharmaceutical · 24 companies
YoY compares companies with prior-year figures
StockShares are +10.9% over a year, behind the all-industry average (+14.9%) — #32 of 53 industries. Over the last month: +4.5%, +7.2pt against the market.Details
GuidanceCompany plans for FY2027 (23 companies combined): revenue +7.3%, operating profit +12.2%. Planned profit growth is below the all-industry plan (+13.0%).Details
Revisions7 raised and 1 cut this year's forecast. The biggest revision: Otsuka (operating profit +35.6%).Details
Latest resultsYear to date through Q1, 11 companies combined: revenue +14.2%, operating profit +55.2% year over year. 9 are ahead of an even pace toward their full-year plan, 8 behind.Details
Disclosures25 TSE filings in the last 90 days (drug development 6, guidance revisions 3, M&A and restructuring 2).Details
Earnings dates15 companies report within 30 days, starting with Kyowa Kirin on Nov 2 and Astellas on Nov 4.Details
| Company | Op. profit (last FY) | This year's plan | Plan change | Revision | Progress (Q2 cumulative) |
|---|---|---|---|---|---|
| ¥408.8B | ¥453.0B | +10.8% | Up +7.9% | 90% |
| ¥36.4B | ¥31.2B | −14.2% | Unchanged | 13% |
| ¥479.4B | ¥488.0B | +1.8% | Up +35.6% | 87% |
| ¥382.6B | ¥395.0B | +3.2% | Unchanged | 47% |
| ¥229.1B | ¥320.0B | +39.7% | Up +1.6% | 61% |
| ¥598.8B | ¥670.0B | +11.9% | Unchanged | 78% |
| ¥44.1B | ¥70.0B | +58.6% | Unchanged | 35% |
| ¥92.2B | ¥94.0B | +1.9% | Unchanged | 62% |
 | ¥166.7B | ¥230.0B | +38.0% | Up +4.5% | 50% |
 | - | ¥130.0B | - | Up +30.0% | 51% |
 | ¥107.3B | ¥104.0B | −3.1% | Up +15.6% | 41% |
 | ¥41.1B | ¥45.0B | +9.4% | Up +2.7% | 30% |
 | ¥47.8B | ¥49.5B | +3.6% | Unchanged | 16% |
 | ¥23.1B | ¥32.0B | +38.5% | Unchanged | 20% |
 | ¥15.9B | ¥27.2B | +71.1% | Unchanged | 18% |
Plans are each company's forecast for the current year from its earnings release. Plan change compares with last year's results; revisions compare the latest forecast with the first one given for the year. Progress is cumulative operating profit ÷ the full-year plan, against an even pace of 25% after Q1, 50% after Q2 and 75% after Q3 (a rough guide for seasonal businesses).
| Change | 1M | 3M | 1Y |
|---|---|---|---|
| Pharmaceutical | +4.5% | +8.4% | +10.9% |
| All industries | −2.7% | −0.9% | +14.9% |
| vs. market | +7.2pt | +9.3pt | −4.0pt |
Rank among industries:3M #7/531Y #32/53
Industry returns are an equal-weighted (geometric) average of member companies. Prices are split-adjusted closes for reference, not real-time.
Totals for the 9 covered companies with full-year results for every year from FY2022 to FY2026. The set is fixed, so adding or removing coverage doesn't move the figures.
Average salary is the reporting entity's figure (often a holding company) from its annual securities report. Holding companies with fewer than 50 staff are excluded.
Shionogi: Acquires IntraBio for $2B to Boost Rare Disease Portfolio
Kobayashi: Receives Take-Private Proposal From NSSK, CVC
Rohto: Rohto Raises FY2030 Sales Outlook, Shifts to Rolling Forecasts for 2031 Targets
| Company | Revenue | YoY | Operating profit | Margin | Share | Average salary | Average age | Employees |
|---|---|---|---|---|---|---|---|---|
| 1 | ¥4.5T | −1.7% | ¥408.8B | 9.1% | 22.8% | ¥11.0M | 43.4 | 4,808 |
| 2 | ¥2.5T | +3.6% | ¥36.4B | 1.5% | 12.6% | ¥7.45M | 47.3 | 2,991 |
| 3 | ¥2.5T | +6.0% | ¥479.4B | 19.4% | 12.5% | ¥10.6M | 44.4 | 183 |
| 4 | ¥2.1T | +11.9% | ¥382.6B | 17.9% | 10.8% | ¥10.5M | 42.3 | 4,105 |
| 5 | ¥2.1T | +12.6% | ¥229.1B | 10.8% | 10.7% | ¥11.0M | 45.0 | 8,009 |
| 6 | ¥1.3T | +7.5% | ¥598.8B | 47.6% | 6.4% | ¥12.1M | 42.5 | 5,026 |
| 7 | ¥825.4B | +4.6% | ¥44.1B | 5.3% | 4.2% | ¥11.2M | 44.5 | 2,979 |
| 8 | ¥515.8B | +5.9% | ¥92.2B | 17.9% | 2.6% | ¥10.2M | 44.2 | 3,464 |
| 9 | ¥499.7B | +14.0% | ¥166.7B | 33.4% | 2.5% | ¥10.0M | 41.5 | 2,129 |
| 10 | ¥496.8B | +0.3% | - | - | 2.5% | ¥9.94M | 43.2 | 4,013 |
| 11 | ¥453.3B | +13.7% | ¥107.3B | 23.7% | 2.3% | ¥9.06M | 44.5 | 1,747 |
| 12 | ¥343.7B | +11.4% | ¥41.1B | 12.0% | 1.7% | ¥8.26M | 42.3 | 1,753 |
| 13 | ¥291.6B | −2.8% | ¥47.8B | 16.4% | 1.5% | ¥9.02M | 43.8 | 1,884 |
| 14 | ¥273.7B | +5.4% | ¥23.1B | 8.4% | 1.4% | ¥6.95M | 35.5 | 2,899 |
| 15 | ¥201.7B | +6.7% | ¥15.9B | 7.9% | 1.0% | ¥9.38M | 43.7 | 110 |
16 | ¥192.6B | +6.4% | ¥35.2B | 18.3% | 1.0% | ¥9.11M | 41.9 | 2,858 |
17 | ¥170.8B | +6.6% | ¥35.5B | 20.8% | 0.9% | ¥9.19M | 41.4 | 1,876 |
18 | ¥165.7B | +0.1% | ¥14.9B | 9.0% | 0.8% | ¥7.57M | 41.0 | 1,665 |
19 | ¥97.4B | +10.3% | ¥-2.9B | -3.0% | 0.5% | ¥7.98M | 42.7 | 1,297 |
20 | ¥89.2B | +2.1% | ¥12.4B | 13.9% | 0.5% | ¥7.99M | 42.7 | 872 |
21 | ¥76.9B | −18.3% | ¥-899M | -1.2% | 0.4% | ¥8.75M | 41.9 | 1,086 |
| 22 | ¥40.3B | +21.9% | ¥555M | 1.4% | 0.2% | ¥8.19M | 41.4 | 937 |
| 23 | ¥29.6B | +2.7% | ¥-8.5B | -28.6% | 0.1% | ¥12.6M | 46.8 | 50 |
| 24 | ¥18.5B | −60.3% | ¥-5.0B | -27.1% | 0.1% | ¥11.7M | 39.7 | 157 |
| Industry total / average | ¥19.8T | +5.0% | ¥2.8T | 13.9% | 100% | ¥9.57M | 42.8 | 56,898 |
Revenue and operating profit are from each company's latest full-year results. Green margins are at or above the industry margin. Financial institutions may not report operating profit.
Otsuka: Lifts H1 Net Profit Forecast 68% on Strong Drug Sales, Cost Cuts
Otsuka: Ends buyback, to cancel 4.54m shares, or 0.84%
